Vitaeris, Inc. is a company that provides Clazakizumab, Monoclonal antibody, Chronic inflammatory disease and more. Vitaeris, Inc. is headquartered in Canada British Columbia. Vitaeris, Inc. was founded in 2016. Vitaeris, Inc. has a total of 107 patents
visualizing technology portfolio of hot application areas and blank areas for Vitaeris, Inc.
Time Range:
Overall
Overall
1 year
3 year
5 year
Application Domain L2
Application Domain L2
Application Domain L3
Application Domain L4
High-Tech Industry L1
High-Tech Industry L2
Tech Topic L2
Tech Topic L3
Timeline
Tech Topic L2
Tech Topic L2
Tech Topic L3
High-Tech Industry L1
High-Tech Industry L2
Application Domain L2
Application Domain L3
Application Domain L4
Download
Subsidiary Lists
Subsidiaries with patent applications for Vitaeris, Inc.
Sign up to view the full data
Free Trial Now
Download
Vitaeris, Inc. Frequently Asked Questions
What technical fields has Vitaeris, Inc. researched?
Vitaeris, Inc. has researched the technical fields related toClazakizumabMonoclonal antibodyChronic inflammatory diseaseCelecoxibTocilizumabInterleukinRituximabBiopharmaceuticalAutoinjectorSewing needleCoronavirus disease 2019 (COVID-19)InjectorSyringeKidney transplant rejectionDiclofenac/MisoprostolZolmitriptanTapentadolSumatriptanCapsaicin
Vitaeris has licensed global exclusive rights to the best-in-class anti-interleukin-6 monoclonal antibody Clazakizumab from Alder Biopharmaceuticals, and...
What is Vitaeris, Inc.'s official website?
Vitaeris, Inc.'s official website is http://www.vitaerisbio.com.